Skip to main content

Market Overview

UPDATE: Piper Jaffray Reiterates on Medtronic


In a report published Wednesday, Piper Jaffray analyst Brooks West reiterated an Overweight rating on Medtronic (NYSE: MDT) and raised the price target from $58.00 to $68.00.

In the report, Piper Jaffray says "Medtronic delivered 3.3% cc revenue growth in F2Q14 (Oct) with revenue of $4.194B topping consensus expectations of $4.180B and EPS of $0.91 beating consensus $0.90 by a penny. Revenue growth was led by a strong rebound in ICD sales, up 4% cc, as sell through of next generation Viva CRT-Ds and Evera ICDs made up for reported weakness due to launch cadence in F1Q. With key recent US launches in MDT's Diabetes and Neuro franchises and improving core markets offsetting weakness in Spine, we believe MDT can reach or exceed the high-end of its 3-4% cc revenue guidance, setting the company on a mid single-digit growth trajectory with multiple key product launches on the horizon in FY15. Reiterate OW rating and raising PT to $68."

Medtronic closed on Tuesday at $57.94.

Latest Ratings for MDT

Jun 2021Argus ResearchMaintainsBuy
May 2021CitigroupMaintainsBuy
May 2021Deutsche BankMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!

Posted-In: Brooks West Piper JaffrayAnalyst Color Reiteration Analyst Ratings

Latest Ratings

MANTMorgan StanleyMaintains90.0
MGPWolfe ResearchInitiates Coverage On43.0
OHIWolfe ResearchInitiates Coverage On43.0
QUREBTIGInitiates Coverage On46.0
KRCWolfe ResearchInitiates Coverage On88.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at